Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 122 points (0.7%) at 17,066 as of Monday, July 14, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,069 issues advancing vs. 930 declining with 155 unchanged. The Drugs industry currently sits up 1.5% versus the S&P 500, which is up 0.5%. Top gainers within the industry include Perrigo ( PRGO), up 5.9%, Mylan ( MYL), up 2.7%, Grifols ( GRFS), up 2.4%, Shire ( SHPG), up 1.9% and Novartis ( NVS), up 0.8%. A company within the industry that fell today was Vertex Pharmaceuticals ( VRTX), up 0.9%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Abbott Laboratories ( ABT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Abbott Laboratories is up $0.43 (1.0%) to $41.73 on average volume. Thus far, 3.5 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 5.6 million shares. The stock has ranged in price between $41.50-$41.95 after having opened the day at $41.95 as compared to the previous trading day's close of $41.30. Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $61.9 billion and is part of the health care sector. Shares are up 7.8% year-to-date as of the close of trading on Friday. Currently there are 10 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and weak operating cash flow. Get the full Abbott Laboratories Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.